Invokana Lawsuit in Early Stages of Development Post FDA Warning

April 18, 2016 – – TheProductLawyers.com announces that it has recently published details to the FDA concerning side effects among users of the Type II diabetes medication Invokana, including potentially deadly kidney-related problems. Based on reports to the FDA, which collates adverse effect reports, more than 50 complaints have recently been made that may tie Invokana to the possible progression of kidney disabilities and malfunction in some users. These complaints were received during the medication’s first year of sales.

Invokana is a SGLT2 class inhibitor, which is intended to help people with Type II diabetes control their glucose levels by reducing the excessive amount of sugar in the blood that can be absorbed by the kidneys, enabling the sugar to be expelled from the body during urination.

Invokana and other SGLT2 class inhibitor users have been alerted by the FDA to keep a watch for any symptoms of renal damage, some of which may include chronic exhaustion, dry skin, rashes, nausea, weight loss, and headaches.

Invokana is also cited in a 2015 QuarterWatch newsletter released by the ISMP (Institute for Safe Medication Practices) as having a potential relation to kidney difficulties. It describes potential links between Invokana and the hundreds of major health complications experienced by users during the product’s inaugural year, and 54 of these complaints mentioned renal failure or kidney dysfunction.

Banville Law attorneys support an informational site at TheProductLawyers.com, and they are currently offering free consultations to individuals who might have taken Invokana or other SGLT2 class inhibitors and are now experiencing health conditions that they suspect might have been brought on by their use of the products.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009388